Amyloidosis

被引:483
作者
Pepys, MB [1 ]
机构
[1] UCL Royal Free & Univ, Coll Med Sch, Dept Med, Ctr Amyloidosis & Acute Phase Prot, London NW3 2PF, England
来源
ANNUAL REVIEW OF MEDICINE | 2006年 / 57卷
基金
英国医学研究理事会;
关键词
amyloid fibril; diagnosis; imaging; treatment;
D O I
10.1146/annurev.med.57.121304.131243
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Amyloidosis is a clinical disorder caused by extracellular deposition of insoluble abnormal fibrils, derived from aggregation of misfolded, normally soluble, protein. About 23 different unrelated proteins are known to form amyloid fibrils in vivo, which share a pathognomonic structure although they are associated with clinically distinct conditions. Systemic amyloidosis, with amyloid deposits in the viscera, blood vessel walls, and connective tissue, is usually fatal and is the cause of about one per thousand deaths in developed countries. This rarity and the variable involvement of different organs and tissues are often responsible for missed or delayed diagnosis, and amyloidosis remains a considerable clinical challenge. However, recent elucidation of important aspects of pathogenesis, as well as developments in diagnosis, monitoring, and treatment, have greatly improved outcomes, especially when patients are managed in specialist centers.
引用
收藏
页码:223 / 241
页数:19
相关论文
共 48 条
[1]   Quantitative analysis of serum free light chains - A new marker for the diagnostic evaluation of primary systemic amyloidosis [J].
Abraham, RS ;
Katzmann, JA ;
Clark, RJ ;
Bradwell, AR ;
Kyle, RA ;
Gertz, MA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (02) :274-278
[2]   Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death [J].
Arrasate, M ;
Mitra, S ;
Schweitzer, ES ;
Segal, MR ;
Finkbeiner, S .
NATURE, 2004, 431 (7010) :805-810
[3]   Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene [J].
Botto, M ;
Hawkins, PN ;
Bickerstaff, MCM ;
Herbert, J ;
Bygrave, AE ;
McBride, A ;
Hutchinson, WL ;
Tennent, GA ;
Walport, MJ ;
Pepys, MB .
NATURE MEDICINE, 1997, 3 (08) :855-859
[4]  
Bradwell AR, 2001, CLIN CHEM, V47, P673
[5]   Natural oligomers of the amyloid-protein specifically disrupt cognitive function [J].
Cleary, JP ;
Walsh, DM ;
Hofmeister, JJ ;
Shankar, GM ;
Kuskowski, MA ;
Selkoe, DJ ;
Ashe, KH .
NATURE NEUROSCIENCE, 2005, 8 (01) :79-84
[6]   Autologous stem cell transplantation for primary systemic amyloidosis [J].
Comenzo, RL ;
Gertz, MA .
BLOOD, 2002, 99 (12) :4276-4282
[7]   Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins [J].
Dispenzieri, A ;
Kyle, RA ;
Gertz, MA ;
Therneau, TM ;
Miller, WL ;
Chandrasekaran, K ;
McConnell, JP ;
Burritt, MF ;
Jaffe, AS .
LANCET, 2003, 361 (9371) :1787-1789
[8]   Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma [J].
Drayson, M ;
Tang, LX ;
Drew, R ;
Mead, GP ;
Carr-Smith, H ;
Bradwell, AR .
BLOOD, 2001, 97 (09) :2900-2902
[9]   Myoglobin forms amyloid fibrils by association of unfolded polypeptide segments [J].
Fändrich, M ;
Forge, V ;
Buder, K ;
Kittler, M ;
Dobson, CM ;
Diekmann, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15463-15468
[10]   Stem cell transplantation for the management of primary systemic amyloidosis [J].
Gertz, MA ;
Lacy, MQ ;
Dispenzieri, A ;
Gastineau, DA ;
Chen, MG ;
Ansell, SM ;
Inwards, DJ ;
Micallef, INM ;
Tefferi, A ;
Litzow, MR .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (07) :549-555